Meta-analysis reaffirms safety, efficacy of intermittent biologic use
According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.
According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.
López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.
A study revealed that patients with actinic keratosis reported feeling more pain during red light PDT compared to simulated daylight PDT.
A study found that in addition, recovery time was both quick and yielded minimal symptoms.
A decision from the FDA is expected in the second half of 2024.
Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.
Alexa Hetzel, MS, PA-C, leads a discussion on the role both physician assistants and nurse practitioners play in diagnosis and management of plaque psoriasis, commenting…
Keep up with the latest headlines in dermatology from the past week, including the appointment of All Detergent’s first chief dermatology advisor, Incyte’s acquisition of…
ICYMI, this week we had news about a study of upadacitinib versus dupilumab in atopic dermatitis, the European Union’s approval of bimekizumab for HS, and…
Mona Shahriari, MD, and a plaque psoriasis patient provide insights into the mechanism of action and benefits of tapinarof cream 1% as a nonsteroidal topical.
Study findings suggest OCT’s effectiveness in accurately diagnosing and mapping BCC, with a high predictive capability for Mohs surgery requirements.